Patents Examined by John Ulm
  • Patent number: 9944910
    Abstract: Disclosed herein are compositions and formulations containing a TATk-CDKL5 fusion protein. Also disclosed are methods of producing a TATk-CDKL5 fusion protein from vectors containing a TATk-CDKL5 cDNA and methods of transducing cells with the vectors containing a TATk-CDKL5 cDNA and the TATk-CDKL5 fusion protein.
    Type: Grant
    Filed: March 21, 2016
    Date of Patent: April 17, 2018
    Assignee: Alma Mater Studiorum—Università di Bologna
    Inventors: Elisabetta Ciani, Franco Laccone
  • Patent number: 9901551
    Abstract: Provided herein are compositions and methods for treating diabetes, obesity, and other metabolic diseases, disorders or conditions with chemosensory receptor ligands. Also provided herein are pharmaceutical compositions useful for the methods of the present invention.
    Type: Grant
    Filed: April 20, 2010
    Date of Patent: February 27, 2018
    Assignee: AMBRA BIOSCIENCE LLC
    Inventors: Alain Baron, Martin R. Brown, Christopher R. J. Jones
  • Patent number: 9862751
    Abstract: There is provided a peptide which is capable of binding to an MHC molecule in vitro and being presented to a T cell without antigen processing (i.e. an apitope) which peptide comprises a portion of the region 40-60 of myelin oligodendrocyte glycoprotein (MOG). In particular there is provided an apitope which is selected from the following myelin oligodendrocyte glycoprotein peptides: MOG 41-55, 43-57, 44-58 and 45-59. There is also provided the use of such a peptide in a pharmaceutical composition and a method to treat and/or prevent a disease using such a peptide.
    Type: Grant
    Filed: January 13, 2014
    Date of Patent: January 9, 2018
    Assignee: APITOPE TECHNOLOGY (BRISTOL) LIMITED
    Inventors: David Wraith, Heather Streeter
  • Patent number: 9855332
    Abstract: The present invention is directed to methods for treating diarrhea, both chronic or acute forms, by the administration of a therapeutically or prophylactically effective amount of antibodies and fragments thereof having binding specificity for CGRP. In particular the methods prevent or reduce diarrhea in conditions or treatments resulting in elevated CGRP levels, e.g., in the GI tract (colon) that are associated with diarrhea and/or improper electrolyte and fluid excretion from the bowel or urinary system. More specifically, this invention relates to treatments using the anti-CGRP antibodies and fragments described herein, and binding fragments thereof.
    Type: Grant
    Filed: May 21, 2012
    Date of Patent: January 2, 2018
    Assignee: ALDERBIO HOLDINGS LLC
    Inventors: Andrew F. Russo, Eric A. Kaiser, Ana Recober, Adisa Kuburas, Ann C. Raddant, Brian Robert Kovacevich, John A. Latham, Jeffrey T. L. Smith, Leon F. Garcia-Martinez
  • Patent number: 9851355
    Abstract: The present invention relates generally to methods of determining the response to metadoxine therapy for the treatment of Fragile X Syndrome and other cognitive disorders. The invention also relates to identifying individuals that will be responsive to metadoxine therapy.
    Type: Grant
    Filed: September 9, 2014
    Date of Patent: December 26, 2017
    Assignee: Alcobra Ltd.
    Inventors: Yaron Daniely, Jonathan Rubin, Johanna Schumann
  • Patent number: 9850290
    Abstract: Provided herein are compositions comprising light-activated chimeric proteins expressed on plasma membranes and methods of using the same to selectively depolarize excitatory or inhibitory neurons.
    Type: Grant
    Filed: May 5, 2016
    Date of Patent: December 26, 2017
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Karl Deisseroth, Ofer Yizhar, Lief Fenno, Peter Hegemann, Matthias Prigge
  • Patent number: 9834593
    Abstract: The present invention is based on the discovery of polyclonal IgG's ability to promote Schwann cell maturation, differentiation, and myelin production. Methods for treating non-idiopathic, demyelinating peripheral neuropathies in mammals, where the neuropathy is not immune-mediated or infection-mediated, through the administration of polyclonal IgG are provided. Types of demyelinating peripheral neuropathies treatable with the present invention include peripheral nerve trauma and toxin-induced peripheral neuropathies. Alternatively, a composition of polyclonal IgGs can be applied directly to a peripheral nerve cell to induce maturation, differentiation into a myelinating state, and myelin expression or promote cell survival.
    Type: Grant
    Filed: February 18, 2015
    Date of Patent: December 5, 2017
    Assignees: Baxalta Incorporated, Baxalta GmbH
    Inventors: Patrick Küry, Nevena Tzekova, Hans-Peter Hartung, Corinna Hermann, Birgit Maria Reipert, Hans-Peter Schwarz, Hartmut Ehrlich, Sebastian Bunk
  • Patent number: 9809627
    Abstract: The present disclosure describes cyclized peptides that inhibit A? toxicity and therefore can be used as therapeutic agents to treat Alzheimer's Disease.
    Type: Grant
    Filed: October 15, 2015
    Date of Patent: November 7, 2017
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Regina M. Murphy, Patricia Y. Cho, Jeffrey A. Johnson, Xiaomeng Lu
  • Patent number: 9809862
    Abstract: Provided herein are GPCR-based chemical biosensors that can have a sensing unit, a processing unit, and a response unit that can be used to detect a chemical of interest. Also provided herein are methods of making and using the GPCR-based chemical biosensors.
    Type: Grant
    Filed: August 11, 2015
    Date of Patent: November 7, 2017
    Assignee: Georgia Tech Research Corporation
    Inventors: Pamela Peralta-Yahya, Kuntal Mukherjee, Souryadeep Bhattacharyya, Stephen Sarria
  • Patent number: 9804157
    Abstract: This invention relates to assays which screen for compounds that modulate taste elicited by the T1R2/T1R3 sweet taste receptor which include a novel counter screen to eliminate false positives. In addition, the invention contemplates assays which screen for compounds that modulate taste elicited by the T1R1/T1R3 umami taste receptor which include a novel counter screen to eliminate false positives. Preferably the assays are conducted in high throughput format thereby enabling the screening of many hundreds of different compounds whereby the counter screen significantly improves assay efficiency. Further, the invention relates to the use of the compounds identified in the subject screening assays to modulate T1R associated taste perception.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: October 31, 2017
    Assignee: SENOMYX, INC.
    Inventors: Guy Servant, Nicole Servant
  • Patent number: 9796768
    Abstract: The present invention relates to the ability of specialized non-naturally occurring peptides to bind to sodium channels and inhibit activation of the sodium channels. The invention further relates to methods for regulating of sodium absorption and fluid volume and treating disorders responsive to modulating sodium absorption by modulating the binding of specialized non-naturally occurring peptides to sodium channels.
    Type: Grant
    Filed: April 21, 2017
    Date of Patent: October 24, 2017
    Assignees: Spryx Biosciences, Inc., The University of North Carolina at Chapel Hill
    Inventors: Robert Tarran, Dale J. Christensen
  • Patent number: 9797883
    Abstract: The present invention relates to generating hiPSC-derived cardiomyocytes and embryoid bodies that recapitulate the disease phenotype of Long QT Syndrome and their use in developing pharmacological treatments thereof. The present invention also includes the use of a compound which inhibits the ubiquitin-proteasome pathway for the preparation of a medicament for the prophylaxis or treatment of a disease associated with prolonged ventricular repolarization (cardiac arrhythmia) caused by one or more mutations in the amino acid sequence of the hERG potassium channel.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: October 24, 2017
    Assignee: Singapore Health Services Pte Ltd
    Inventors: Winston Se Ngie Shim, Ashish Mehta, Chrishan Julian Alles Ramachandra, Philip En Hou Wong
  • Patent number: 9790265
    Abstract: Newly identified mammalian taste-cell-specific G protein-coupled receptors, and the genes and cDNA encoding said receptors are described. Specifically, T1R G protein-coupled receptors active in taste signaling, and the genes and cDNA encoding the same, are described, along with methods for isolating such genes and for isolating and expressing such receptors. Methods for representing taste perception of a particular taste stimulus in a mammal are also described, as are methods for generating novel molecules or combinations of molecules that elicit a predetermined taste perception in a mammal, and methods for simulating one or more tastes. Further, methods for stimulating or blocking taste perception in a mammal are also disclosed.
    Type: Grant
    Filed: May 18, 2015
    Date of Patent: October 17, 2017
    Assignee: SENOMYX, INC.
    Inventors: Jon Elliot Adler, Xiaodong Li, Lena Luukkonen, Shawn O'Connell, Sergey Zozulya
  • Patent number: 9775876
    Abstract: Embodiments herein generally relate to methods, compositions and uses of CaMKII inhibitors. Other embodiments relate to methods, compositions and uses of agents that target CaMKII. Yet further embodiments relate to compositions, methods and uses of CaMKIIN-derived molecules and other CaMKII inhibitor molecules that inhibit autonomous CaMKII activity. In accordance with these embodiments, compositions that inhibit autonomous CaMKII activity may be used for treating conditions causing neuronal cell death, for treating cancer or for treating neurodegenerative disorders.
    Type: Grant
    Filed: September 17, 2015
    Date of Patent: October 3, 2017
    Assignee: THE REGENTS OF THE UNIVERSITY OF COLORADO, a body corporate
    Inventors: K. Ulrich Bayer, Steve Coultrap
  • Patent number: 9778258
    Abstract: The present invention relates to the discovery that specific human taste receptors in the T2R taste receptor family respond to particular bitter compounds. Also, the invention relates to the discovery of specific hT2R9 alleles and their disparate activity in functional assays with the same bitter ligands. The invention further relates to the use of these T2R receptors in assays for identifying ligands that modulate the activation of these taste receptors by specific bitter ligands and related compounds. These compounds may be used as additives and/or removed from foods, beverages, cosmetics and medicinals in order to modify (block) T2R-associated bitter taste. Also T2R ligands may be used as therapeutics to treat and modulate T2R associated gastrointestinal and metabolic functions as well as treat gastrointestinal and metabolic diseases such as eating disorders, food sensing, food absorption, obesity, diabetes, Crohn's disease, celiac disease, et al.
    Type: Grant
    Filed: August 26, 2015
    Date of Patent: October 3, 2017
    Assignee: SENOMYX, INC.
    Inventors: Xiaodong Li, Hong Xu, Qing Li, Huixian Tang, Alexey Pronin
  • Patent number: 9778270
    Abstract: Newly identified mammalian taste-cell-specific G Protein-Coupled Receptors and the genes encoding said receptors are described. Specifically, T2R taste G Protein-Coupled Receptors that are believed to be involved in bitter taste sensation, and the genes encoding the same, are described, along with methods for isolating such genes and for isolating and expressing such receptors. Methods for representing taste perception of a particular tastant in a mammal are also described, as are methods for generating a novel molecules or combinations of molecules that elicit a predetermined taste perception in a mammal, and methods for simulating one or more tastes.
    Type: Grant
    Filed: September 10, 2015
    Date of Patent: October 3, 2017
    Assignee: SENOMYX, INC.
    Inventor: Jon Elliot Adler
  • Patent number: 9766236
    Abstract: This disclosure provides a taste receptor internalization assay useful for identifying taste modulators.
    Type: Grant
    Filed: May 9, 2014
    Date of Patent: September 19, 2017
    Assignee: PEPSICO, INC.
    Inventors: Yuliya Kurash, Stephen Gravina
  • Patent number: 9750747
    Abstract: The invention provides a drug selected from eslicarbazepine acetate and eslicarbazepine, for use in treating or preventing a disorder selected from epilepsy, affective disorders, schizoaffective disorders, bipolar disorders, neuropathic pain and neuropathic pain related disorders, attention disorders, anxiety disorders, sensorimotor disorders, vestibular disorders, and fibromyalgia, in a patient suffering from or susceptible to absence seizures.
    Type: Grant
    Filed: August 24, 2012
    Date of Patent: September 5, 2017
    Assignee: BAIL-PORTELA & CA, S.A.
    Inventor: Patricio Manuel Vieira Araujo Soares Da Silva
  • Patent number: 9751943
    Abstract: Antibodies, and particularly human antibodies, are disclosed that demonstrate activity in the treatment of demyelinating diseases as well as other diseases of the central nervous system that are of viral, bacterial or idiopathic origin, including neural dysfunction caused by spinal cord injury. Neuromodulatory agents are set forth that include and comprise a material selected from the group consisting of an antibody capable of binding structures or cells in the central nervous system, a peptide analog, a hapten, active fragments thereof, agonists thereof, mimics thereof, monomers thereof and combinations thereof. Methods are described for treating demyelinating diseases, and diseases of the central nervous system of humans and domestic animals, using polyclonal IgM antibodies and human monoclonal antibodies sHIgm22(LYM 22), sHIgm46(LYM46) ebvHIgM MSI19D10, CB2bG8, AKJR4, CB2iE12, CB2iE7, MSI19E5 and MSI10E10, active fragments thereof and the like.
    Type: Grant
    Filed: January 23, 2015
    Date of Patent: September 5, 2017
    Assignees: ACORDA THERAPEUTICS, INC., MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
    Inventors: Elliott A. Gruskin, Arthur E. Warrington, Allan J. Bieber, Moses Rodriguez, Eric Walter Theodore Chojnicki
  • Patent number: 9745373
    Abstract: The present invention is directed to antibodies and fragments thereof having binding specificity for CGRP. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the VH, VL and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-CGRP antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-CGRP antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-CGRP antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with CGRP.
    Type: Grant
    Filed: May 21, 2012
    Date of Patent: August 29, 2017
    Assignee: ALDERBIO HOLDINGS LLC
    Inventors: Brian Robert Kovacevich, Leon F. Garcia-Martinez, Katie Olson, Benjamin H. Dutzar, Jens J. Billgren, John A. Latham, Danielle M. Mitchell, Patricia Dianne Mcneill, Nicole M. Janson, Maria-Cristina Loomis